New Funding to Help 3DBioFibR Advance its Biopolymer Fiber Manufacturing

3DBioFibR Inc. is $3 million richer, having attracted equity financing from both new and existing investors, including AoA Innovation Fund, Build Ventures, Invest Nova Scotia, and Concrete Ventures.

The funding follows a string of recently signed paid partnerships and collaborations across key sectors—including tissue engineering, medical devices, defense, cosmetics, and apparel, with several multinational corporations.

“This investment fuels the next phase of our growth,” 3DBioFibR CEO Kevin Sullivan stated. “It enables us to meet growing demand from our commercial partners and to become a qualified supplier for regulated medical and therapeutic applications. ISO 13485 certification is a key step in delivering clinical-grade fibers at the scale and consistency our partners require. We’re excited to expand our impact across industries that urgently need stronger, more sustainable biomaterials.”

The financing will help 3DBioFibR improve its operational scale and deepen its role as a critical supplier of next-generation biomaterials. The funds also will enable the company to increase its manufacturing capacity, foster operational growth, and implement ISO 13485 certification, including building a clean room manufacturing facility—essential for producing medical-grade materials.

Over the past two years, 3DBioFibR has secured paid development agreements with global and regional companies developing products in tissue engineering, medical devices, defense, cosmetics, and apparel. These partnerships focus on integrating 3DBioFibR’s best-in-class fibers into existing and developing product pipelines. The new capital ensures the company can continue to deliver high-performance materials at commercial scale, while laying the groundwork for expanded clinical partnerships.

“3DBioFibR has accomplished something rare, translating cutting-edge biomaterials science into real commercial traction,” Build Ventures General Partner Patrick Keefe said. “They’ve partnered with serious players in global industries and built a manufacturing platform that can deliver fibers at a scale and quality the market hasn’t seen before. This team is setting the benchmark in biopolymer fiber manufacturing, and we’re proud to support their journey.”

3DBioFibR’s proprietary dry-spinning platform produces fibers from various biopolymers—currently more than six—with performance metrics that meet or exceed natural tissue strength by two to three times. Compared to conventional techniques like wet spinning and electrospinning, 3DBioFibR’s process delivers material at more than 3,600 times the scale, with vastly improved uniformity and cost-efficiency. These properties position the company’s fibers for use in applications where strength, biocompatibility, or scale have previously been limiting factors.

“As an early investor in 3DBioFibR, Invest Nova Scotia has been active with the company throughout its growth into a unique business that offers novel and unparalleled manufacturing potential for biopolymer applications, representing multibillion-dollar market opportunities,” said Lidija Marušić, Invest Nova Scotia. “With this latest investment, Invest Nova Scotia looks forward to seeing 3DBioFibR achieve their objectives.”

3DBioFibR develops biomaterials in regenerative medicine, medical devices, defense, cosmetics, and sustainable textiles. Its patented dry-spinning technology enables scalable, high-precision manufacturing of advanced biopolymer fibers—delivering superior performance at industrial scales. By collaborating with industry leaders, 3DBioFibR is unlocking transformative applications for strong, lightweight, and biocompatible materials across some of the world’s most demanding sectors.